- "Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination"
Capitini CM, Davis JP, Larabee SM, et al., Biol Blood Marrow Transplant 17 (6): 790-799 Jun 2011. We demonstrate that ECP-treated splenocytes attenuate GVHD irrespective of the source of ECP-treated cells via a mechanism that likely involves modulation of DCs and requires IL-10 produced by BM-derived cells. Importantly, the attenuation of GVHD by ECP-treated splenocytes permits donor lymphocyte infusion-dependent responses to DC vaccines after allo-BMT. Pubmed.
- "Identification and characterization of two Bordetella avium gene products required for hemagglutination"
Temple LM, Miyamoto DM, Mehta M, et al., Infect Immun 78 (6): 2370-2376 Jun 2010. We report the use of transposon mutagenesis to identify two genes required for hemagglutination. The genes (hagA and hagB) were adjacent and divergently oriented and had no orthologs in the genomes of other Bordetella species. Pubmed.
- "Immunotherapy of childhood cancer: from biologic understanding to clinical application"
Wayne AS, Capitini CM, Mackall CL, Curr Opin Pediatr 22 (1): 2-11 Feb 2010. Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Immunotherapy holds promise in the treatment of children and adolescents with cancer and has the potential to improve both survival and quality of life. Pubmed.
- "Immune-based therapeutics for pediatric cancer"
Capitini CM, Mackall CL, Wayne AS, Expert Opin Biol Ther 10 (2): 163-178 Feb 2010. Some immune-based therapies, such as ch14.18 and MTP-PE, have already been proven effective in phase III randomized trials. Further studies are needed to optimize and integrate other therapies into standard regimens, and to test them in randomized trials for patients with childhood cancer. Pubmed.